WO2021211408A1 - Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules - Google Patents
Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules Download PDFInfo
- Publication number
- WO2021211408A1 WO2021211408A1 PCT/US2021/026791 US2021026791W WO2021211408A1 WO 2021211408 A1 WO2021211408 A1 WO 2021211408A1 US 2021026791 W US2021026791 W US 2021026791W WO 2021211408 A1 WO2021211408 A1 WO 2021211408A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- compound according
- isopropyl
- triazolo
- nmr
- Prior art date
Links
- 102000029749 Microtubule Human genes 0.000 title claims description 25
- 108091022875 Microtubule Proteins 0.000 title claims description 25
- 210000004688 microtubule Anatomy 0.000 title claims description 25
- 230000000087 stabilizing effect Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 116
- 238000000034 method Methods 0.000 claims abstract description 67
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 22
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- -1 3-methoxy-8-azabicyclo[3.2.1]octan-8-yl Chemical group 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 230000009529 traumatic brain injury Effects 0.000 claims description 12
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 125000003725 azepanyl group Chemical group 0.000 claims description 9
- 208000017004 dementia pugilistica Diseases 0.000 claims description 9
- 125000003386 piperidinyl group Chemical group 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 7
- 208000034799 Tauopathies Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 6
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 230000001010 compromised effect Effects 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000002346 iodo group Chemical group I* 0.000 claims description 4
- 230000003252 repetitive effect Effects 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 104
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 62
- 238000005160 1H NMR spectroscopy Methods 0.000 description 43
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 43
- 238000000746 purification Methods 0.000 description 42
- 235000019439 ethyl acetate Nutrition 0.000 description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
- 238000004007 reversed phase HPLC Methods 0.000 description 26
- 239000007787 solid Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 238000010898 silica gel chromatography Methods 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 102000004243 Tubulin Human genes 0.000 description 11
- 108090000704 Tubulin Proteins 0.000 description 11
- 239000003085 diluting agent Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- AMPTXTDNZWKPEY-UHFFFAOYSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1F)F)Cl)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1F)F)Cl)N=CN=2 AMPTXTDNZWKPEY-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 8
- NPLJIXHHJQZJRB-UHFFFAOYSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1)F)Cl)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1)F)Cl)N=CN=2 NPLJIXHHJQZJRB-UHFFFAOYSA-N 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical compound BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 description 7
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 238000011105 stabilization Methods 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- OTJZCIYGRUNXTP-UHFFFAOYSA-N but-3-yn-1-ol Chemical compound OCCC#C OTJZCIYGRUNXTP-UHFFFAOYSA-N 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- SNMLKBMPULDPTA-REOHCLBHSA-N (2s)-1,1,1-trifluoropropan-2-amine Chemical compound C[C@H](N)C(F)(F)F SNMLKBMPULDPTA-REOHCLBHSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- ZRGQHQYCICNNMX-UHFFFAOYSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)I)F)Cl)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)I)F)Cl)N=CN=2 ZRGQHQYCICNNMX-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 229910019213 POCl3 Inorganic materials 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- OSVXSBDYLRYLIG-UHFFFAOYSA-N chlorine dioxide Inorganic materials O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 4
- 239000000039 congener Substances 0.000 description 4
- QVOUNCFCMIXFDB-UHFFFAOYSA-N diethyl 2-(4-cyano-2,6-difluorophenyl)propanedioate Chemical compound C(#N)C1=CC(=C(C(=C1)F)C(C(=O)OCC)C(=O)OCC)F QVOUNCFCMIXFDB-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- JOZZAIIGWFLONA-RXMQYKEDSA-N (2r)-3-methylbutan-2-amine Chemical compound CC(C)[C@@H](C)N JOZZAIIGWFLONA-RXMQYKEDSA-N 0.000 description 3
- ZUZPCOQWSYNWLU-VIFPVBQESA-N 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-n-[(2s)-1,1,1-trifluoropropan-2-yl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine Chemical compound FC1=CC(OCCCNC)=CC(F)=C1C1=C(N[C@@H](C)C(F)(F)F)N2N=CN=C2N=C1Cl ZUZPCOQWSYNWLU-VIFPVBQESA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- SRNKZYRMFBGSGE-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CN=C21 SRNKZYRMFBGSGE-UHFFFAOYSA-N 0.000 description 3
- 150000001345 alkine derivatives Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229950004708 cevipabulin Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- CRWVOXFUXPYTRK-UHFFFAOYSA-N pent-4-yn-1-ol Chemical compound OCCCC#C CRWVOXFUXPYTRK-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 229910052717 sulfur Chemical group 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- YGGUXSPKQBCCRM-SCSAIBSYSA-N (2r)-1,1,1-trifluoro-3-methylbutan-2-amine Chemical compound CC(C)[C@@H](N)C(F)(F)F YGGUXSPKQBCCRM-SCSAIBSYSA-N 0.000 description 2
- DXSUORGKJZADET-RXMQYKEDSA-N (2r)-3,3-dimethylbutan-2-amine Chemical compound C[C@@H](N)C(C)(C)C DXSUORGKJZADET-RXMQYKEDSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- SQHSJJGGWYIFCD-UHFFFAOYSA-N (e)-1-diazonio-1-dimethoxyphosphorylprop-1-en-2-olate Chemical compound COP(=O)(OC)C(\[N+]#N)=C(\C)[O-] SQHSJJGGWYIFCD-UHFFFAOYSA-N 0.000 description 2
- 102100027831 14-3-3 protein theta Human genes 0.000 description 2
- QVFQVODIUDKALS-SECBINFHSA-N 4-[5-chloro-7-[[(2R)-3-methylbutan-2-yl]amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorobenzonitrile Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1F)F)N[C@H](C)C(C)C)N=CN=2 QVFQVODIUDKALS-SECBINFHSA-N 0.000 description 2
- YLPFRLDTXRREAB-ZETCQYMHSA-N 4-[5-chloro-7-[[(2S)-1,1,1-trifluoropropan-2-yl]amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3-fluorobenzonitrile Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1)F)N[C@H](C(F)(F)F)C)N=CN=2 YLPFRLDTXRREAB-ZETCQYMHSA-N 0.000 description 2
- POJWVKFCIHEARQ-UHFFFAOYSA-N 4-[7-(azepan-1-yl)-5-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorobenzonitrile Chemical compound N1(CCCCCC1)C1=C(C(=NC=2N1N=CN=2)Cl)C1=C(C=C(C#N)C=C1F)F POJWVKFCIHEARQ-UHFFFAOYSA-N 0.000 description 2
- RPWKNJPADUPJJE-UHFFFAOYSA-N 4-[7-(azepan-1-yl)-5-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3-fluorobenzonitrile Chemical compound N1(CCCCCC1)C1=C(C(=NC=2N1N=CN=2)Cl)C1=C(C=C(C#N)C=C1)F RPWKNJPADUPJJE-UHFFFAOYSA-N 0.000 description 2
- ZHCMLGWKJKQHTQ-UHFFFAOYSA-N 5,7-dichloro-2h-triazolo[4,5-d]pyrimidine Chemical class N1=C(Cl)N=C(Cl)C2=NNN=C21 ZHCMLGWKJKQHTQ-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- AEKZOGGZXFZKAV-CYBMUJFWSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCCO)F)N[C@H](C)C(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCCO)F)N[C@H](C)C(C)C)N=CN=2 AEKZOGGZXFZKAV-CYBMUJFWSA-N 0.000 description 2
- CRBMSEOQBIRNEI-CQSZACIVSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCN(C)C)F)N[C@H](C)C(C)(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCN(C)C)F)N[C@H](C)C(C)(C)C)N=CN=2 CRBMSEOQBIRNEI-CQSZACIVSA-N 0.000 description 2
- KASUEFCOLNVEIA-CYBMUJFWSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCN(C)C)F)N[C@H](C)C(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCN(C)C)F)N[C@H](C)C(C)C)N=CN=2 KASUEFCOLNVEIA-CYBMUJFWSA-N 0.000 description 2
- 208000018652 Closed Head injury Diseases 0.000 description 2
- 206010010254 Concussion Diseases 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001499 aryl bromides Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- ILBIXZPOMJFOJP-UHFFFAOYSA-N n,n-dimethylprop-2-yn-1-amine Chemical compound CN(C)CC#C ILBIXZPOMJFOJP-UHFFFAOYSA-N 0.000 description 2
- 230000012106 negative regulation of microtubule depolymerization Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 150000002825 nitriles Chemical group 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 229940031826 phenolate Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- BWNQTGRBVMERHU-UHFFFAOYSA-N tert-butyl n-but-3-ynylcarbamate Chemical compound CC(C)(C)OC(=O)NCCC#C BWNQTGRBVMERHU-UHFFFAOYSA-N 0.000 description 2
- QVMLIHFGUIRVKU-UHFFFAOYSA-N tert-butyl n-methyl-n-prop-2-ynylcarbamate Chemical compound C#CCN(C)C(=O)OC(C)(C)C QVMLIHFGUIRVKU-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- DDRXUCIAWFPHKZ-NUBCRITNSA-N (2R)-3,3-dimethylbutan-2-amine hydrochloride Chemical compound [Cl-].CC([C@@H](C)[NH3+])(C)C DDRXUCIAWFPHKZ-NUBCRITNSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 0 *c(nc1nc2*)n[n]1c(N(*)*)c2-c1c(*)cc(*)cc1* Chemical compound *c(nc1nc2*)n[n]1c(N(*)*)c2-c1c(*)cc(*)cc1* 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-N 2,2-diethylpropanedioic acid Chemical class CCC(CC)(C(O)=O)C(O)=O LTMRRSWNXVJMBA-UHFFFAOYSA-N 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- XFKYJMGXZXJYBS-UHFFFAOYSA-N 3,4,5-trifluorobenzonitrile Chemical compound FC1=CC(C#N)=CC(F)=C1F XFKYJMGXZXJYBS-UHFFFAOYSA-N 0.000 description 1
- BTBFCBQZFMQBNT-UHFFFAOYSA-N 3,4-difluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1F BTBFCBQZFMQBNT-UHFFFAOYSA-N 0.000 description 1
- NAOUKDPJPWIYSB-SECBINFHSA-N 4-[5-chloro-7-[[(2R)-3,3-dimethylbutan-2-yl]amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorobenzonitrile Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1F)F)N[C@H](C)C(C)(C)C)N=CN=2 NAOUKDPJPWIYSB-SECBINFHSA-N 0.000 description 1
- WFNHEWORQHUUDL-SNVBAGLBSA-N 4-[5-chloro-7-[[(2R)-3,3-dimethylbutan-2-yl]amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3-fluorobenzonitrile Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1)F)N[C@H](C)C(C)(C)C)N=CN=2 WFNHEWORQHUUDL-SNVBAGLBSA-N 0.000 description 1
- UAGPLIIWRJWBFG-SNVBAGLBSA-N 4-[5-chloro-7-[[(2R)-3-methylbutan-2-yl]amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3-fluorobenzonitrile Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1)F)N[C@H](C)C(C)C)N=CN=2 UAGPLIIWRJWBFG-SNVBAGLBSA-N 0.000 description 1
- CKXCEVOBMSSYDI-LURJTMIESA-N 4-[5-chloro-7-[[(2S)-1,1,1-trifluoropropan-2-yl]amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorobenzonitrile Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1F)F)N[C@H](C(F)(F)F)C)N=CN=2 CKXCEVOBMSSYDI-LURJTMIESA-N 0.000 description 1
- YSTZALVEERZMFJ-UHFFFAOYSA-N 4-[7-(azocan-1-yl)-5-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorobenzonitrile Chemical compound N1(CCCCCCC1)C1=C(C(=NC=2N1N=CN=2)Cl)C1=C(C=C(C#N)C=C1F)F YSTZALVEERZMFJ-UHFFFAOYSA-N 0.000 description 1
- YVRKIWZRRQDYOM-UHFFFAOYSA-N 4-[7-(azocan-1-yl)-5-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3-fluorobenzonitrile Chemical compound N1(CCCCCCC1)C1=C(C(=NC=2N1N=CN=2)Cl)C1=C(C=C(C#N)C=C1)F YVRKIWZRRQDYOM-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- FRUHHVIOSKAPJF-UHFFFAOYSA-N 5,7-dichloro-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound FC1=CC(F)=CC(F)=C1C1=C(Cl)N2N=CN=C2N=C1Cl FRUHHVIOSKAPJF-UHFFFAOYSA-N 0.000 description 1
- OXAOZXUXEGURKA-UHFFFAOYSA-N 5,7-dichloro-6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound ClC1=NC2=NC=NN2C(Cl)=C1C1=CC=CC=C1 OXAOZXUXEGURKA-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OVWNPHLTLUJKES-UHFFFAOYSA-L C(#N)C1=CC(=C(C(=C1)F)C=1C(=NC=2N(C=1[O-])N=CN=2)[O-])F.[Na+].[Na+] Chemical compound C(#N)C1=CC(=C(C(=C1)F)C=1C(=NC=2N(C=1[O-])N=CN=2)[O-])F.[Na+].[Na+] OVWNPHLTLUJKES-UHFFFAOYSA-L 0.000 description 1
- URTSGGQINNKNCP-UHFFFAOYSA-L C(#N)C1=CC(=C(C=C1)C=1C(=NC=2N(C=1[O-])N=CN=2)[O-])F.[Na+].[Na+] Chemical compound C(#N)C1=CC(=C(C=C1)C=1C(=NC=2N(C=1[O-])N=CN=2)[O-])F.[Na+].[Na+] URTSGGQINNKNCP-UHFFFAOYSA-L 0.000 description 1
- LHGSNMFMUPKRTN-OAHLLOKOSA-N C(C)(C)(C)OC(NCCC#CC1=CC(=C(C(=C1)F)C=1C(=NC=2N(C=1N[C@H](C)C(C)(C)C)N=CN=2)Cl)F)=O Chemical compound C(C)(C)(C)OC(NCCC#CC1=CC(=C(C(=C1)F)C=1C(=NC=2N(C=1N[C@H](C)C(C)(C)C)N=CN=2)Cl)F)=O LHGSNMFMUPKRTN-OAHLLOKOSA-N 0.000 description 1
- UZGOIQFHPGALQH-OAHLLOKOSA-N C(C)(C)(C)OC(NCCC#CC1=CC(=C(C(=C1)F)C=1C(=NC=2N(C=1N[C@H](C)C(C)C)N=CN=2)Cl)F)=O Chemical compound C(C)(C)(C)OC(NCCC#CC1=CC(=C(C(=C1)F)C=1C(=NC=2N(C=1N[C@H](C)C(C)C)N=CN=2)Cl)F)=O UZGOIQFHPGALQH-OAHLLOKOSA-N 0.000 description 1
- JTURVCIZZGXQIC-UHFFFAOYSA-L C1(=CC=CC=C1)C=1C(=NC=2N(C=1[O-])N=CN=2)[O-].[Na+].[Na+] Chemical compound C1(=CC=CC=C1)C=1C(=NC=2N(C=1[O-])N=CN=2)[O-].[Na+].[Na+] JTURVCIZZGXQIC-UHFFFAOYSA-L 0.000 description 1
- WYBQAPBSVRGLLR-GFCCVEGCSA-N CC(C)[C@@H](C)N1[F]c(cc(cc2F)C#CCCO)c2-c2c1[n]1nc(C)nc1nc2Cl Chemical compound CC(C)[C@@H](C)N1[F]c(cc(cc2F)C#CCCO)c2-c2c1[n]1nc(C)nc1nc2Cl WYBQAPBSVRGLLR-GFCCVEGCSA-N 0.000 description 1
- ZDHXBFDSRRGLRQ-YFKPBYRVSA-N C[C@@H](C(F)(F)F)NC1=C(C(=NC2=NC=NN12)Cl)C3=C(C=C(C=C3F)I)F Chemical compound C[C@@H](C(F)(F)F)NC1=C(C(=NC2=NC=NN12)Cl)C3=C(C=C(C=C3F)I)F ZDHXBFDSRRGLRQ-YFKPBYRVSA-N 0.000 description 1
- NBEYJPJMXBKBFF-CYBMUJFWSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1)F)N[C@@H](C(F)(F)F)C(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1)F)N[C@@H](C(F)(F)F)C(C)C)N=CN=2 NBEYJPJMXBKBFF-CYBMUJFWSA-N 0.000 description 1
- IFGLFKXMGWJAIP-UHFFFAOYSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1F)F)N1CCCCC1)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1F)F)N1CCCCC1)N=CN=2 IFGLFKXMGWJAIP-UHFFFAOYSA-N 0.000 description 1
- OAVDFJGSIMRUHJ-CYBMUJFWSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1F)F)N[C@@H](C(F)(F)F)C(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C#N)C=C1F)F)N[C@@H](C(F)(F)F)C(C)C)N=CN=2 OAVDFJGSIMRUHJ-CYBMUJFWSA-N 0.000 description 1
- VVAMQHBZVGPCDG-SNVBAGLBSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#C)F)N[C@H](C)C(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#C)F)N[C@H](C)C(C)C)N=CN=2 VVAMQHBZVGPCDG-SNVBAGLBSA-N 0.000 description 1
- BJHFBUCIEZULAL-MZCHFKTASA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCC(O)([2H])[2H])F)N[C@H](C)C(C)(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCC(O)([2H])[2H])F)N[C@H](C)C(C)(C)C)N=CN=2 BJHFBUCIEZULAL-MZCHFKTASA-N 0.000 description 1
- UHBZCYBMAWTMRC-JTQLQIEISA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCCO)F)N[C@H](C(F)(F)F)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCCO)F)N[C@H](C(F)(F)F)C)N=CN=2 UHBZCYBMAWTMRC-JTQLQIEISA-N 0.000 description 1
- MKADUIMXZJUNTD-CYBMUJFWSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCCO)F)N[C@H](C)C(C)(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCCO)F)N[C@H](C)C(C)(C)C)N=CN=2 MKADUIMXZJUNTD-CYBMUJFWSA-N 0.000 description 1
- XWKIKUIAPWBJLA-CYBMUJFWSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCO)F)N([C@H](C)C(C)C)C)N=C(N=2)C Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCO)F)N([C@H](C)C(C)C)C)N=C(N=2)C XWKIKUIAPWBJLA-CYBMUJFWSA-N 0.000 description 1
- BVFWWECJJMKPSD-VIFPVBQESA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCO)F)N[C@H](C(F)(F)F)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCO)F)N[C@H](C(F)(F)F)C)N=CN=2 BVFWWECJJMKPSD-VIFPVBQESA-N 0.000 description 1
- BJHFBUCIEZULAL-GFCCVEGCSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCO)F)N[C@H](C)C(C)(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCO)F)N[C@H](C)C(C)(C)C)N=CN=2 BJHFBUCIEZULAL-GFCCVEGCSA-N 0.000 description 1
- ZTDNAZRYTWFZTM-GFCCVEGCSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCO)F)N[C@H](C)C(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCCO)F)N[C@H](C)C(C)C)N=CN=2 ZTDNAZRYTWFZTM-GFCCVEGCSA-N 0.000 description 1
- YHESFGFRVSPOHO-OAHLLOKOSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCN(C(OC(C)(C)C)=O)C)F)N[C@H](C)C(C)(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCN(C(OC(C)(C)C)=O)C)F)N[C@H](C)C(C)(C)C)N=CN=2 YHESFGFRVSPOHO-OAHLLOKOSA-N 0.000 description 1
- IPHMXRUKTHXYSW-OAHLLOKOSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCN(C(OC(C)(C)C)=O)C)F)N[C@H](C)C(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCN(C(OC(C)(C)C)=O)C)F)N[C@H](C)C(C)C)N=CN=2 IPHMXRUKTHXYSW-OAHLLOKOSA-N 0.000 description 1
- NVTYRMIMGIIOCP-CYBMUJFWSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCN(C)C)F)N[C@H](C)C(C)(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)C#CCN(C)C)F)N[C@H](C)C(C)(C)C)N=CN=2 NVTYRMIMGIIOCP-CYBMUJFWSA-N 0.000 description 1
- FIMAZBBVSVSTGY-MRVPVSSYSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)I)F)N[C@H](C)C(C)(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)I)F)N[C@H](C)C(C)(C)C)N=CN=2 FIMAZBBVSVSTGY-MRVPVSSYSA-N 0.000 description 1
- POOZUBOILDSCGO-MRVPVSSYSA-N ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)I)F)N[C@H](C)C(C)C)N=CN=2 Chemical compound ClC1=NC=2N(C(=C1C1=C(C=C(C=C1F)I)F)N[C@H](C)C(C)C)N=CN=2 POOZUBOILDSCGO-MRVPVSSYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- ILHQWJYAJOTAGF-UHFFFAOYSA-N FC1=C(C(=CC(=C1)I)F)C(C(=O)OCC)C(=O)OCC Chemical compound FC1=C(C(=CC(=C1)I)F)C(C(=O)OCC)C(=O)OCC ILHQWJYAJOTAGF-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- IIJDVGLYEWAXLA-UHFFFAOYSA-N IC1=NC2=C(C=N1)NN=N2 Chemical compound IC1=NC2=C(C=N1)NN=N2 IIJDVGLYEWAXLA-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- FHOVXCYETWSIPX-UHFFFAOYSA-N NC1=CC(=C(C(=C1)F)C(C(=O)OCC)C(=O)OCC)F Chemical compound NC1=CC(=C(C(=C1)F)C(C(=O)OCC)C(=O)OCC)F FHOVXCYETWSIPX-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000007791 alzheimer disease like pathology Effects 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 230000007854 axonal transport deficit Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- BKIDTHZCPKFGEA-UHFFFAOYSA-N diethyl 2-(4-cyano-2-fluorophenyl)propanedioate Chemical compound C(#N)C1=CC(=C(C=C1)C(C(=O)OCC)C(=O)OCC)F BKIDTHZCPKFGEA-UHFFFAOYSA-N 0.000 description 1
- FGYDHYCFHBSNPE-UHFFFAOYSA-N diethyl phenylmalonate Chemical compound CCOC(=O)C(C(=O)OCC)C1=CC=CC=C1 FGYDHYCFHBSNPE-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WSCWSMUKWIYUFV-UHFFFAOYSA-N n,n-dimethylbut-3-yn-1-amine Chemical compound CN(C)CCC#C WSCWSMUKWIYUFV-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 210000002511 neuropil thread Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention is directed to compounds and methods for the treatment of cancer or neurodegenerative tauopathies such as Alzheimer's disease and frontotemporal lobar degeneration.
- BACKGROUND [0004]
- Neurodegenerative tauopathies including Alzheimer’s disease (AD) are characterized by the misfolding and aggregation of the microtubule (MT)-associated protein tau. Normally, tau binds to and stabilizes MTs, thereby maintaining the network of MTs essential for axonal transport in neurons.
- AD tau becomes sequestered into aggregates, known as neurofibrillary tangles (NFTs) and neuropil threads, resulting in reduced MT-binding.
- NFTs neurofibrillary tangles
- neuropil threads resulting in reduced MT-binding.
- MT function may be compromised
- Other neurodegenerative diseases where MT function may be compromised include frontotemporal lobar degeneration, multiple sclerosis, Parkinson's disease, amyotrophic laterial sclerosis, schizophrenia, Huntington’s disease, multiple sclerosis, and traumatic brain injury (TBI), especially repetitive TBI (rTBI) such as that due to dementia pugilistica and recurrent football concussions and military closed head injuries, which also is known as chronic traumatic encephalopathy (CTE).
- CTE chronic traumatic encephalopathy
- This compound like vincristine, can interact with tubulin heterodimers and interfere with the rate of exchange of the guanosine triphosphate (GTP) and, thus, competes with vincristine but not taxol or colchicine, for binding to MTs.
- GTP guanosine triphosphate
- Cevipabulin (Compound 1) [0008] Opposite to the activity of vincristine/vinblastine, triazolopyrimidine Compound 2, binds exclusively to MTs and not to unpolymerized tubulin heterodimers. See Sáez-Calvo, “Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin,” Cell Chemical Biology, 2017, 24, 737-750 e6. Compound 2 [0009] Triazolopyrimidine structural modifications can promote MT stabilization or disrupt MT integrity. These differences can have important and unknown ramifications in the therapeutic applications of triazolopyrimidines, including exhibiting different binding modes.
- R 1 is Cl
- R 2 is CH(CH 3 )CF 3 , CH(isopropyl)CF 3 , CH(isopropyl)CH 3 , CH(tert-butyl)CH 3 , or CH(methyl diazirinyl)CH 3 , wherein R 2 may optionally be mono- or poly-deuterated
- R 3 is H or alkyl; or, R 2 and R 3 , together with the N atom to which they are attached, form a C 5 -C 7 heterocyclic ring or 3-methoxy-8-azabicyclo[3.2.1]octan-8-yl
- R 4 is H or F
- R 5 is H or F
- R 6 is iodo, cyano, ethyl
- compositions for treating a neurodegenerative disease or cancer comprising a therapeutically effective amount of a compound according to Formula I, and methods of treating a neurodegenerative disease or cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to Formula I.
- MT Microtubule
- TPDs triazolo[1,5-a] pyrimidines
- the present inventors have previously characterized a number of MT-stabilizing and MT-destabilizing TPDs. For example, U.S. Pat.
- No.9,649,317 discloses methods of use for such compounds.
- the present disclosure provides novel TPDs containing specified C6-phenyl substitutions.
- Prior investigation into the MT stabilizing properties of TPD’s in cell-based assays of MT-stabilization revealed that varying substitution patterns result in molecules that can either promote MT stabilization or conversely disrupt MT stabilization.
- the SAR work led to the synthesis of novel C6 nitrile and alkyne substituted TPDs, as described herein.
- microtubule-stabilizing compounds will be useful in treating neurodegenerative diseases, in particular, tauopathies, for example, Alzheimer's disease, frontotemporal lobar degeneration, Pick's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration.
- tauopathies for example, Alzheimer's disease, frontotemporal lobar degeneration, Pick's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration.
- the compounds of the invention may be useful for other diseases where tau pathology is a co-morbidity or where microtubule function is compromised, for example, schizophrenia, Parkinson's disease (PD), PD with dementia, Lewy body disease with dementia, and amyotrophic lateral sclerosis.
- the compounds of the invention can also be used to treat traumatic brain injury (TBI), especially repetitive TBI (rTBI), such as that due to dementia pugilistica and recurrent football concussions and military closed head injuries such as that due to IEDs, which also is known as chronic traumatic encephalopathy (CTE), with features of tauopathy or AD-like pathology. It is speculated that CTE also may emerge from PTSD.
- TBI traumatic brain injury
- rTBI repetitive TBI
- CTE chronic traumatic encephalopathy
- a reference to “a material” is a reference to at least one of such materials and equivalents thereof known to those skilled in the art, and so forth.
- a value is expressed as an approximation by use of the descriptor “about” it will be understood that the particular value forms another embodiment.
- use of the term “about” indicates approximations that can vary depending on the desired properties sought to be obtained by the disclosed subject matter and is to be interpreted in the specific context in which it is used, based on its function. The person skilled in the art will be able to interpret this as a matter of routine.
- the number of significant figures used for a particular value may be one non-limiting method of determining the extent of the word “about”.
- gradations used in a series of values may be used to determine the intended range available to the term “about” for each value.
- all ranges are inclusive and combinable. That is, references to values stated in ranges include every value within that range. [0018] When a list is presented, unless stated otherwise, it is to be understood that each individual element of that list and every combination of that list is to be interpreted as a separate embodiment.
- alkyl refers to an optionally substituted, saturated straight, or branched, hydrocarbon radical having from about 1 to about 20 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein).
- alkyl may refer to a substituted or unsubstituted, straight or branched hydrocarbon radical having about 1-20, 1-15, 1-10, 1-8, 1-6, 1-5, 1-4, or 1-3 carbon atoms. In some embodiments, “alkyl” refers to an unsubstituted, straight radical having about 1-6 carbon atoms.
- alkyl can mean “alkylene”; for example, if X is –R 1 R 2 , and R 1 is said to be “alkyl”, then “alkyl” may correctly be interpreted to mean “alkylene”.
- Heterocyclyl or “heterocyclic” refers to a stable 3- to 18-membered non- aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, the only heteroatom is the nitrogen atom to which R 2 and R 3 are attached. Whenever it appears herein, a numerical range such as “3 to 18” refers to each integer in the given range, e.g., "3 to 18 ring atoms” means that the heterocyclyl group may consist of 3 ring atoms, 4 ring atoms, et cetera, up to and including 18 ring atoms.
- the heterocyclyl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems.
- the heteroatoms in the heterocyclyl radical may be optionally oxidized.
- One or more nitrogen atoms, if present, are optionally quaternized.
- the heterocyclyl radical is partially or fully saturated.
- the heterocyclyl may be attached to the rest of the molecule through any atom of the ring(s).
- heterocyclyl radicals include, but are not limited to, azepanyl, azocanyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thia
- Heterocyclyl may also includes bicyclic ring systems wherein one non-aromatic ring, usually with 3 to 7 ring atoms, contains at least 2 carbon atoms in addition to 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, as well as combinations comprising at least one of the foregoing heteroatoms; and the other ring, usually with 3 to 7 ring atoms, optionally contains 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen and is not aromatic.
- a heterocyclyl moiety is optionally substituted with one, two, or three substituents selected from halo (F, Cl, Br, or I, preferably F), -OH, -OC 1 - 6 alkyl, -CN, -NH 2 , -NH(C 1-6 alkyl), -NH(C 1-6 alkyl) 2 , C 3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl.
- each individual embodiment is deemed to be combinable with any other embodiment(s) and such a combination is considered to be another embodiment.
- various features of the invention that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any sub-combination.
- the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
- each said step may also be considered an independent embodiment in itself.
- stereoisomeric forms of the compounds of Formula I are also within the scope of the invention, as are pharmaceutically acceptable salts of any compound or stereoisomer of Formula I.
- stereoisomers refers to all enantiomerically/diastereomerically pure and enantiomerically/diastereomerically enriched compounds of the invention.
- R 3 is H or alkyl. In certain embodiments, R 3 is H. In other embodiments R 3 is alkyl, such as C 1 -C 6 alkyl.
- R6 is iodo. In some of these embodiments, R 4 and R 5 are both F, and R 3 is H. In the embodiments in which R 4 and R 5 are both F, R 2 may be, for example, CH(CH 3 )CF 3 , CH(isopropyl)CF 3 , CH(isopropyl)CH 3 , or CH(tert-butyl)CH 3 . [0027] In certain embodiments of the present compounds, R6 is cyano. In some of these embodiments, R 4 and R 5 are both F.
- R 2 may be CH(CH 3 )CF 3 , CH(isopropyl)CF 3 , CH(isopropyl)CH 3 , or CH(tert-butyl)CH 3 .
- R 4 and R 5 are both F
- R 2 and R 3 together with the N atom to which they are attached, may form piperidinyl, azepanyl, or azocanyl.
- R 6 is cyano
- R 4 is H and R 5 is F.
- R 2 may be CH(CH 3 )CF 3 , CH(isopropyl)CF 3 , CH(isopropyl)CH 3 , or CH(tert-butyl)CH 3 .
- R 2 and R 3 together with the N atom to which they are attached, form piperidinyl, azepanyl, or azocanyl.
- R 6 is ethynyl.
- R 4 and R 5 may both be F.
- R 2 may be CH(CH 3 )CF 3 , CH(isopropyl)CF 3 , CH(isopropyl)CH 3 , or CH(tert-butyl)CH 3 .
- R 2 and R 3 together with the N atom to which they are attached, form piperidinyl, azepanyl, or azocanyl.
- R 6 is ethynyl
- R 4 is H and R 5 is F.
- R 2 is CH(CH 3 )CF 3 , CH(isopropyl)CF 3 , CH(isopropyl)CH 3 , or CH(tert-butyl)CH 3 .
- R 2 and R 3 together with the N atom to which they are attached, form piperidinyl, azepanyl, or azocanyl.
- R 6 is -C ⁇ C-(CH 2 ) n -R 7.
- n is 1-3.
- R4 and R5 are both F.
- compositions for treating a neurodegenerative disease or cancer comprising a therapeutically effective amount of a compound according to any one of the embodiments described above. Also disclosed are methods of treating a neurodegenerative disease or cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to any any one of the embodiments described above.
- the phrase “therapeutically effective amount” refers to the amount of active compound that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following: (1) at least partially preventing the disease or condition or a symptom thereof; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease; (2) inhibiting the disease or condition; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., including arresting further development of the pathology and/or symptomatology); and (3) at least partially ameliorating the disease or condition; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e.,
- the compound according to the present disclosure may be provided in a composition that is formulated for any type of administration.
- the compositions may be formulated for administration orally, topically, parenterally, enterally, or by inhalation.
- the active compound may be formulated for neat administration, or in combination with conventional pharmaceutical carriers, diluents, or excipients, which may be liquid or solid.
- the applicable solid carrier, diluent, or excipient may function as, among other things, a binder, disintegrant, filler, lubricant, glidant, compression aid, processing aid, color, sweetener, preservative, suspensing/dispersing agent, tablet-disintegrating agent, encapsulating material, film former or coating, flavoring agent, or printing ink.
- a binder disintegrant, filler, lubricant, glidant, compression aid, processing aid, color, sweetener, preservative, suspensing/dispersing agent, tablet-disintegrating agent, encapsulating material, film former or coating, flavoring agent, or printing ink.
- Any material used in preparing any dosage unit form is preferably pharmaceutically pure and substantially non-toxic in the amounts employed.
- the active compound may be incorporated into sustained-release preparations and formulations.
- Administration in this respect includes administration by, inter alia, the following routes: intravenous, intramuscular, subcutaneous, intraocular, intrasynovial, transepithelial including transdermal, ophthalmic, sublingual and buccal; topically including ophthalmic, dermal, ocular, rectal and nasal inhalation via insufflation, aerosol, and rectal systemic.
- the carrier, diluent, or excipient may be a finely divided solid that is in admixture with the finely divided active ingredient.
- the active ingredient is mixed with a carrier, diluent or excipient having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
- the active compound may be incorporated with the carrier, diluent, or excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- the amount of active compound(s) in such therapeutically useful compositions is preferably such that a suitable dosage will be obtained.
- Liquid carriers, diluents, or excipients may be used in preparing solutions, suspensions, emulsions, syrups, elixirs, and the like.
- the active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid such as water, an organic solvent, a mixture of both, or pharmaceutically acceptable oils or fat.
- the liquid carrier, excipient, or diluent can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, or osmo-regulators.
- suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, or osmo-regulators.
- Suitable solid carriers, diluents, and excipients may include, for example, calcium phosphate, silicon dioxide, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, ethylcellulose, sodium carboxymethyl cellulose, microcrystalline cellulose, polyvinylpyrrolidine, low melting waxes, ion exchange resins, croscarmellose carbon, acacia, pregelatinized starch, crospovidone, HPMC, povidone, titanium dioxide, polycrystalline cellulose, aluminum methahydroxide, agar-agar, tragacanth, or mixtures thereof.
- liquid carriers, diluents and excipients for example, for oral, topical, or parenteral administration, include water (particularly containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil), or mixtures thereof.
- the carrier, diluent, or excipient can also be an oily ester such as ethyl oleate and isopropyl myristate.
- sterile liquid carriers diluents, or excipients, which are used in sterile liquid form compositions for parenteral administration.
- Solutions of the active compounds as free bases or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
- a dispersion can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of a dispersion, and by the use of surfactants.
- a coating such as lecithin
- surfactants for example, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium stearate, sodium stearate, and gelatin.
- the active compound may be in the present compositions and methods in an effective amount by any of the conventional techniques well-established in the medical field.
- the administration may be in the amount of about 0.1 mg/day to about 500 mg per day.
- the administration may be in the amount of about 250 mg/kg/day.
- administration may be in the amount of about 0.1 mg/day, about 0.5 mg/day, about 1.0 mg/day, about 5 mg/day, about 10 mg/day, about 20 mg/day, about 50 mg/day, about 100 mg/day, about 200 mg/day, about 250 mg/day, about 300 mg/day, or about 500 mg/day.
- the neurodegenerative disease may be characterized by a tauopathy or compromised microtubule function in the brain of the subject.
- the neurodegenerative disease may be Alzheimer's disease, frontotemporal lobar degeneration, Pick's disease, progressive supranuclear palsy (PSP), corticobasal degeneration, Parkinson's disease (PD), PD with dementia, Lewy body disease with dementia, or amyotrophic lateral sclerosis.
- the neurodegenerative disease is traumatic brain injury or post traumatic stress disorder.
- the traumatic brain injury may be, for example, repetitive traumatic brain injury or chronic traumatic encephalopathy.
- the neurodegenerative disease is schizophrenia.
- the cancer may be a carcinoma, sarcoma, melanoma, lymphoma, or leukemia.
- Common carcinomas include, for example, cancers originating in the skin, lungs, breasts, pancreas, and other organs and glands.
- Sarcomas are represented by cancers that arise in bone, muscle, fat, blood vessels, cartilage, or other soft or connective tissues of the body.
- Exemplary cancers that may be treated in accordance with the present methods include brain cancers such as gliomas and astrocytomas, bladder cancer, breast cancer, colon or rectal cancer, endometrial cancer, kidney cancer, leukemia, liverlung cancer, melanoma, non-hodgkin lymphoma, pancreatic cancer, prostate cancer, or thyroid cancer.
- brain cancers such as gliomas and astrocytomas
- bladder cancer such as gliomas and astrocytomas
- breast cancer breast cancer
- colon or rectal cancer endometrial cancer
- kidney cancer leukemia
- liverlung cancer melanoma
- non-hodgkin lymphoma pancreatic cancer
- prostate cancer or thyroid cancer.
- Example 1- Synthetic Procedure As part of these studies, a total of 73 compounds have been synthesized and tested, including seven previously described triazolopyrimidines; 25 compounds exemplified in the patent literature; and 41 structurally novel congeners. In all cases, the triazolopyrimidine ring was accessed via cyclocondensation reaction between the appropriate diethylmalonate (79–95, Scheme 1) and 1H-1,2,4-triazol-5-amine. Next, treatment with phosphorous oxychloride provided the corresponding 5,7-dichloro triazolopyrimidines (96–112, Scheme 1).
- Example 2 Materials and Methods [0049] All solvents were reagent grade. All reagents were purchased from Aldrich or Acros and used as received. Thin layer chromatography (TLC) was performed with 0.25 mm E. Merck precoated silica gel plates. Silica gel column chromatography was performed with silica gel 60 (particle size 0.040 ⁇ 0.062 mm) supplied by Silicycle and Sorbent Technologies. TLC spots were detected by viewing under a UV light. Melting points (mp) were acquired on a Mel- Temp II (model : 1001) and are uncorrected. Infrared (IR) spectra were recorded on a Bruker, model Alpha spectrometer (part number 1003271/03).
- TLC Thin layer chromatography
- reaction mixture was cooled to room temperature and diluted with H 2 O and EtOAc.
- the organic layer was washed with H 2 O and brine, and the combined aqueous layers were extracted with EtOAc (x3).
- the combined organic layers were dried (MgSO 4 ), filtered, and concentrated.
- the crude products were purified by reverse-phase HPLC.
- the mixture was dried in vacuo and purified by silica gel column chromatography to furnish atropoisomer A as a white solid (29 mg, 0.081 mmol, 39%) and atroposiomer B (23 mg, 0.064 mmol, 30%).
- reaction mixture was cooled to r.t., washed with 1M HCl (50 mL), and extracted with EtOAc (3x). The organic layers were combined, washed with satd. aq. NaCl, dried over anh. Na2SO4, filtered, and concentrated in vacuo.
- Novel C6 nitrile- and alkyne-substituted triazolopyrimidine examples that have improved in vitro activity relative to previously described examples, with the general structure depicted in Formula I.
- the activity of the novel C6-nitrile substituted compounds were tested in a previously described cellular assay of MT-stabilization (Kovalevich, J., et al. (2016)). As summarized in Table 2. below, eighteen examples were synthesized and tested. In all cases, these compounds were confirmed to be active Class I triazolopyrimidines.
- Mouse plasma was obtained from blood that was collected into a 1.5 ml tube containing 0.5M EDTA solution and which was centrifuged for 10 minutes at 4500g at 4oC. Aliquots (50 ⁇ l) of brain homogenates or plasma were mixed with 0.2 ml of acetonitrile, centrifuged at 15,000 x g, and the resulting supernatant was used for subsequent LC- MS/MS analysis.
- the LC-MS/MS analysis was conducted by Inotiv, Inc., utilizing methods essentially as previously described (Lou et al., J. Med. Chem.57:6116-27, 2014). Results are provided in Table 3, below.
- TAL-487 (CNDR-52030) (R)-5-chloro-6-(4-ethynyl-2,6-difluorophenyl)-N-(3-methylbutan-2-yl)-[1,2,4]triazolo[1,5- a]pyrimidin-7-amine.
- the mixture was heated to 170 °C for 3 hours.10 mL of toluene were then added at 110 °C followed by a 50% NaOH solution (1.023 mL, 19.38 mmol, 3 equiv) at 50 °C. Once at rt, the mixture was filtered over sintered glass and rinsed twice with toluene to furnish the bis- phenolate (2.068 g, 6.621 mmol, 97%) that is engaged in the next step without further purification.
- TAL-627 (CNDR-52032) (R)-5-chloro-6-(2,6-difluoro-4-iodophenyl)-N-(3,3-dimethylbutan-2-yl)-[1,2,4]triazolo[1,5- a]pyrimidin-7-amine.
- TAL-555 (CNDR-52035) (R)-5-chloro-6-(4-(3-(dimethylamino)prop-1-yn-1-yl)-2,6-difluorophenyl)-N-(3,3- dimethylbutan-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine.
- TAL-598 (CNDR-52043) (R)-4-(4-(5-chloro-7-((3-methylbutan-2-yl)amino)-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-3,5- difluorophenyl)but-3-yn-1-ol.
- TAL-626 0.040 g, 0.084 mmol
- but-3-yn-1-ol 0.019 mL, 0.018 g, 0.250 mmol
- TAL-599 (CNDR-52044) (R)-5-(4-(5-chloro-7-((3-methylbutan-2-yl)amino)-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-3,5- difluorophenyl)pent-4-yn-1-ol.
- TAL-626 0.027 g, 0.057 mmol
- pent-4-yn-1-ol (0.016 mL, 0.014 g, 0.170 mmol) furnish the title compound as an off- white after purification by reverse phase HPLC and lyophilization (0.012 g, 0.028 mmol, 49%).
- TAL-600 (CNDR-52045) (R)-4-(4-(5-chloro-7-((3,3-dimethylbutan-2-yl)amino)-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)- 3,5-difluorophenyl)but-3-yn-1-ol.
- TAL-627 (0.040 g, 0.081 mmol) and but-3-yn-1-ol (0.018 mL, 0.017 g, 0.240 mmol) furnish the title compound as an off-white after purification by reverse phase HPLC and lyophilization (0.014 g, 0.032 mmol, 40%).
- TAL-601 (CNDR-52046) (R)-5-(4-(5-chloro-7-((3,3-dimethylbutan-2-yl)amino)-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)- 3,5-difluorophenyl)pent-4-yn-1-ol.
- TAL-627 0.040 g, 0.081 mmol
- pent-4-yn-1-ol (0.023 mL, 0.021 g, 0.240 mmol) furnish the title compound as an off-white after purification by reverse phase HPLC and lyophilization (0.036 g, 0.031 mmol, 38%).
- TAL-641 (CNDR-52052) (S)-4-(4-(5-chloro-7-((1,1,1-trifluoropropan-2-yl)amino)-[1,2,4]triazolo[1,5-a]pyrimidin-6- yl)-3,5-difluorophenyl)but-3-yn-1-ol.
- TAL-628 0.032 g, 0.064 mmol
- but-3-yn-1-ol (0.014 mL, 0.013 g, 0.190 mmol) furnish the title compound as an off-white after purification by reverse phase HPLC and lyophilization (0.011 g, 0.025 mmol, 39%).
- TAL-642 (CNDR-52053) (S)-5-(4-(5-chloro-7-((1,1,1-trifluoropropan-2-yl)amino)-[1,2,4]triazolo[1,5-a]pyrimidin-6- yl)-3,5-difluorophenyl)pent-4-yn-1-ol.
- TAL-628 0.033 g, 0.066 mmol
- pent-4-yn-1-ol (0.020 mL, 0.017 g, 0.200 mmol) furnish the title compound as an off-white after purification by reverse phase HPLC and lyophilization (0.010 g, 0.022 mmol, 33%).
- TAL-636 tert-butyl (R)-(3-(4-(5-chloro-7-((3,3-dimethylbutan-2-yl)amino)-[1,2,4]triazolo[1,5- a]pyrimidin-6-yl)-3,5-difluorophenyl)prop-2-yn-1-yl)(methyl)carbamate.
- TAL-651 (CNDR-52054) (R)-4-(4-(5-chloro-7-((3,3-dimethylbutan-2-yl)amino)-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)- 3,5-difluorophenyl)but-3-yn-1,1-d2-1-ol.
- TAL-627 (0.080 g, 0.160 mmol) and but-3-yn-1,1-d2-1-ol (0.035 g, 0.490 mmol) furnish the title compound as an off-white after purification by reverse phase HPLC and lyophilization (0.031 g, 0.071 mmol, 44%).
- TAL-579 (CNDR-52041) (R)-6-(4-(4-aminobut-1-yn-1-yl)-2,6-difluorophenyl)-5-chloro-N-(3-methylbutan-2-yl)- [1,2,4]triazolo[1,5-a]pyrimidin-7-amine hydrochloride.
- TAL- 576 (0.040 g, 0.077 mmol), was converted to the title compound (0.034 g, 0.075 mmol, 97%) as a yellow solid.
- TAL-580 (CNDR-52042) (R)-6-(4-(4-aminobut-1-yn-1-yl)-2,6-difluorophenyl)-5-chloro-N-(3,3-dimethylbutan-2-yl)- [1,2,4]triazolo[1,5-a]pyrimidin-7-amine hydrochloride.
- TAL- 576 (0.040 g, 0.075 mmol), was converted to the title compound (0.034 g, 0.072 mmol, 97%) as a yellow solid.
- TAL-638 (CNDR-52048) (R)-5-chloro-6-(2,6-difluoro-4-(3-(methylamino)prop-1-yn-1-yl)phenyl)-N-(3,3- dimethylbutan-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine hydrochloride.
- TAL-636 (0.035 g, 0.066 mmol), was converted to the title compound (0.028 g, 0.060 mmol, 91%) as a brown solid.
- TAL-665 (CNDR-52056) (R)-4-(4-(5-chloro-2-methyl-7-(methyl(3-methylbutan-2-yl)amino)-[1,2,4]triazolo[1,5- a]pyrimidin-6-yl)-3,5-difluorophenyl)but-3-yn-1-ol.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/995,761 US20230167121A1 (en) | 2020-04-14 | 2021-04-12 | Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules |
CN202180028565.9A CN115397826A (en) | 2020-04-14 | 2021-04-12 | Substituted {1,2,4, } triazolo {1,5-a } pyrimidine compounds and their use for the stabilization of microtubules |
JP2022562242A JP2023521809A (en) | 2020-04-14 | 2021-04-12 | Substituted {1,2,4,}triazolo{1,5-A}pyrimidine compounds and their use in microtubule stabilization |
CA3178865A CA3178865A1 (en) | 2020-04-14 | 2021-04-12 | Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules |
EP21788138.2A EP4136089A4 (en) | 2020-04-14 | 2021-04-12 | Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules |
AU2021255495A AU2021255495A1 (en) | 2020-04-14 | 2021-04-12 | Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063009727P | 2020-04-14 | 2020-04-14 | |
US63/009,727 | 2020-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021211408A1 true WO2021211408A1 (en) | 2021-10-21 |
Family
ID=78084625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/026791 WO2021211408A1 (en) | 2020-04-14 | 2021-04-12 | Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230167121A1 (en) |
EP (1) | EP4136089A4 (en) |
JP (1) | JP2023521809A (en) |
CN (1) | CN115397826A (en) |
AU (1) | AU2021255495A1 (en) |
CA (1) | CA3178865A1 (en) |
WO (1) | WO2021211408A1 (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4579848A (en) * | 1983-07-28 | 1986-04-01 | American Cyanamid Company | 5-substituted[1,2,4]triazolo[1,5-c]pyrimidin-2-amines |
US20060183755A1 (en) * | 2002-12-11 | 2006-08-17 | Fraley Mark E | Tyrosine kinase inhibitors |
US7148227B2 (en) * | 2002-03-21 | 2006-12-12 | Basf Aktiengesellschaft | Fungicidal triazolopyrimidines, methods for producing the same, use thereof for combating harmful fungi and agents containing said substances |
US20070249634A1 (en) * | 2004-06-09 | 2007-10-25 | Carsten Blettner | Triazolopyrimidine Compounds and Use Thereof for Controlling Harmful Fungi |
US7329663B2 (en) * | 2000-06-30 | 2008-02-12 | Wyeth | Substituted-triazolopyrimidines as anticancer agents |
US20080293713A1 (en) * | 2007-04-30 | 2008-11-27 | Abbott Laboratories | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme |
US20130274243A1 (en) * | 2012-02-03 | 2013-10-17 | Pfizer Limited | Chemical Compounds |
WO2019169111A1 (en) * | 2018-03-02 | 2019-09-06 | The Trustees Of The University Of Pennsylvania | [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006100038A1 (en) * | 2005-03-23 | 2006-09-28 | Syngenta Participations Ag | Triazolopyrimidine derivatives useful as fungicides |
AR053343A1 (en) * | 2005-03-23 | 2007-05-02 | Syngenta Participations Ag | DERIVATIVES OF TRIAZOLOPIRIMIDINE WITH FUNGICIDE ACTIVITY, FUNGICIDE COMPOSITIONS THAT CONTAIN THEM AS AN ACTIVE PRINCIPLE AND A METHOD OF CONTROL AND PREVENTION OF INFANT OF PLANTS CONTAINING THEM. |
TWI568737B (en) * | 2014-11-05 | 2017-02-01 | 達特神經科學(開曼)有限責任公司 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as pde2 inhibitors |
EP3585790A1 (en) * | 2017-02-27 | 2020-01-01 | Janssen Pharmaceutica NV | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
-
2021
- 2021-04-12 EP EP21788138.2A patent/EP4136089A4/en active Pending
- 2021-04-12 CA CA3178865A patent/CA3178865A1/en active Pending
- 2021-04-12 AU AU2021255495A patent/AU2021255495A1/en active Pending
- 2021-04-12 JP JP2022562242A patent/JP2023521809A/en active Pending
- 2021-04-12 US US17/995,761 patent/US20230167121A1/en active Pending
- 2021-04-12 WO PCT/US2021/026791 patent/WO2021211408A1/en unknown
- 2021-04-12 CN CN202180028565.9A patent/CN115397826A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4579848A (en) * | 1983-07-28 | 1986-04-01 | American Cyanamid Company | 5-substituted[1,2,4]triazolo[1,5-c]pyrimidin-2-amines |
US7329663B2 (en) * | 2000-06-30 | 2008-02-12 | Wyeth | Substituted-triazolopyrimidines as anticancer agents |
US7148227B2 (en) * | 2002-03-21 | 2006-12-12 | Basf Aktiengesellschaft | Fungicidal triazolopyrimidines, methods for producing the same, use thereof for combating harmful fungi and agents containing said substances |
US20060183755A1 (en) * | 2002-12-11 | 2006-08-17 | Fraley Mark E | Tyrosine kinase inhibitors |
US20070249634A1 (en) * | 2004-06-09 | 2007-10-25 | Carsten Blettner | Triazolopyrimidine Compounds and Use Thereof for Controlling Harmful Fungi |
US20080293713A1 (en) * | 2007-04-30 | 2008-11-27 | Abbott Laboratories | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme |
US20130274243A1 (en) * | 2012-02-03 | 2013-10-17 | Pfizer Limited | Chemical Compounds |
WO2019169111A1 (en) * | 2018-03-02 | 2019-09-06 | The Trustees Of The University Of Pennsylvania | [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules |
Non-Patent Citations (2)
Title |
---|
See also references of EP4136089A4 * |
YUAN, S ET AL.: "Bronsted acid-prompted 'on-water' C(sp3)-H functionalization for the synthesis of isoindolinone/[1,2,4]triazolo[1.5.-a]pyrimidine derivatives targeting the SKP2-CKS1 interaction", CHINESE CHEMICAL LETTERS, vol. 31, no. 2, 10 July 2019 (2019-07-10), pages 349 - 352, XP086008468, DOI: 10.1016/j.cclet. 2019.07.01 9 * |
Also Published As
Publication number | Publication date |
---|---|
EP4136089A4 (en) | 2024-05-29 |
CN115397826A (en) | 2022-11-25 |
JP2023521809A (en) | 2023-05-25 |
US20230167121A1 (en) | 2023-06-01 |
CA3178865A1 (en) | 2021-10-21 |
EP4136089A1 (en) | 2023-02-22 |
AU2021255495A1 (en) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7416365B2 (en) | Apoptosis inducer | |
EP3386981B1 (en) | Heterocycles useful as anti-cancer agents | |
JP5352458B2 (en) | Benzofuro- and benzothienopyrimidine modulators of histamine H4 receptor | |
EP3173412B1 (en) | 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
US20040235841A1 (en) | Cyclic compounds and compositions as protein kinase inhibitors | |
US11932647B2 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
ES2241172T3 (en) | 1- (2-NAFTIL) AND 1- (2-AZANAFTIL) -4- (1-PHENYLMETIL) PIPERAZINAS THAT ARE LIGHTING THE DOPAMINE RECEIVER SUBTIPE D4. | |
EP1799689A1 (en) | Furazano `3, 4-b ! pyrazynes and their use as anti-tumor agents | |
EA010298B1 (en) | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-htreceptor-related disorder | |
US20210198261A1 (en) | Aurora kinase inhibitors and uses thereof | |
CN115298182A (en) | Fused pyrimidine compounds as KCC2 modulators | |
CN109963853B (en) | Compound with activity of degrading tyrosine protein kinase JAK3 | |
AU2021255495A1 (en) | Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules | |
ES2896938T3 (en) | GSK-3 inhibitors | |
ES2874628T3 (en) | Fluoropiperidine compounds as pure 5-HT6 receptor antagonists | |
KR20230065986A (en) | Heterocyclic Compounds as BCL-2 Inhibitors | |
CN114736203A (en) | Heterocyclic compounds as BCL-2 inhibitors | |
RU2782469C2 (en) | Apoptosis-inducing agents | |
TW202408515A (en) | Method of treatment including kras g12c inhibitors and aurora a inhibitors | |
KR101178495B1 (en) | Novel 3,6-disubstituted-4,5,6,7-tetrahydro-1H- pyrazolo[3,4-c]pyridin-7-one compounds and preparation thereof | |
NZ754113A (en) | Indole carboxamide compounds useful as kinase inhibitors | |
NZ754113B2 (en) | Indole carboxamide compounds useful as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21788138 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3178865 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022562242 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021788138 Country of ref document: EP Effective date: 20221114 |
|
ENP | Entry into the national phase |
Ref document number: 2021255495 Country of ref document: AU Date of ref document: 20210412 Kind code of ref document: A |